Lymphoma News

NEW ORLEANS — A shorter initial course of higher-dose dexamethasone failed to reduce toxicity vs. the standard regimen among children and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma, according to study results.

NEW ORLEANS — Adults undergoing stem cell transplant who received a nonrestrictive diet had similar rates of infection, feeding outcomes and acute graft-versus-host disease as those on a low-microbial protective diet, according to a study.

Up to one-quarter of those seeking clinical trial enrollment for novel front-line therapies to treat diffuse large B-cell lymphoma are excluded based on organ function laboratory values, study results showed.

Higher allostatic load, a measure of lifelong stress, correlated with increased risk for cancer mortality, especially among younger populations, according to study results published in SSM Population Health.

Patient navigation programs have historically been difficult to implement on a large scale.

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

A dramatic rise in global incidence of early-onset cancers over the past 30 years may be related in part to increased exposure to risk factors at a young age, according to study results published in Nature Reviews Clinical Oncology,

The treatment landscape of lymphoma has expanded rapidly within the last year, including recent FDA approvals and new designations of drugs in the pipeline.

Treatment regimens for diffuse large B-cell lymphoma have seen many recent advancements, thanks in large part to the development of targeted agents.

The FDA granted priority review to epcoritamab for treatment of certain patients with advanced lymphoma, according to the agent’s manufacturer.